Cervical intraepithelial neoplasia

QIAGEN and Inovio Collaborate to Develop Companion Diagnostic for Novel Immunotherapy Targeting Precancerous Cervical Lesions

Retrieved on: 
Thursday, May 16, 2019
Women, Health, Biotechnology, Genetics, Infectious diseases, Oncology, Pharmaceutical, Research, Consumer, Science, Cancer, Neoplasms, Health, Infectious causes of cancer, RTT, Papillomavirus, Medical software, Qiagen, Cervical intraepithelial neoplasia, Human papillomavirus infection, Precancerous condition, Papilloma

QIAGEN N.V. (NYSE:QGEN; Frankfurt Prime Standard:QIA) and Inovio Pharmaceuticals Inc. (NASDAQ:INO) today announced a collaboration to co-develop a companion diagnostic to guide clinical decision-making for the use of Inovios DNA-based immunotherapy to treat cervical dysplasia caused by human papillomavirus (HPV).

Key Points: 
  • QIAGEN N.V. (NYSE:QGEN; Frankfurt Prime Standard:QIA) and Inovio Pharmaceuticals Inc. (NASDAQ:INO) today announced a collaboration to co-develop a companion diagnostic to guide clinical decision-making for the use of Inovios DNA-based immunotherapy to treat cervical dysplasia caused by human papillomavirus (HPV).
  • We are pleased to support Inovio by developing a liquid biopsy-based companion diagnostic to identify patients who would benefit from VGX-3100, which has potential to make a dramatic difference in the detection of HPV infections and treatment of precancerous disease.
  • The project progressed into development and Inovio now aims to make regulatory submissions for VGX-3100 in 2021.
  • QIAGEN is bringing their extensive track record of commercially developing and marketing novel diagnostic tests to this important collaboration.

The human papillomavirus (HPV) therapeutics market will register a CAGR of nearly 9% by 2023

Retrieved on: 
Tuesday, February 12, 2019
Cancer, Infectious causes of cancer, Papillomavirus, Gynaecological cancer, RTT, Carcinogenesis, Human papillomavirus infection, Pap test, Colposcopy, Papillomaviridae, HPV vaccine, Cervical intraepithelial neoplasia

The diagnostic methods that are currently available in the market include Pap test, colposcopy, and HPV DNA test.

Key Points: 
  • The diagnostic methods that are currently available in the market include Pap test, colposcopy, and HPV DNA test.
  • Technavio's analysts have predicted that the human papillomavirus (HPV) therapeutics market will register a CAGR of nearly 9% by 2023.
  • The global HPV therapeutics market witnessed strong advances in terms of prevention of diseases caused by HPV.
  • For the detailed list of factors that will drive and challenge the growth of the human papillomavirus (HPV) therapeutics market during the 2019-2023, view our report.

Global Women's Health Drugs Market to 2024 - Influx of New Products Including Orilissa, Relugolix and Bremelanotide to Diversify Landscape and Drive Growth

Retrieved on: 
Monday, January 21, 2019
RTT, Chemistry, Medicine, Women\'s health, Cervical intraepithelial neoplasia, Intraepithelial neoplasia, Infertility, Polycystic ovary syndrome, Endometriosis, Cin, Elagolix, Ovarian cancer

The "Global Women's Health Drugs Market to 2024 - Influx of New Products Including Orilissa, Relugolix and Bremelanotide to Diversify Landscape and Drive Growth" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Women's Health Drugs Market to 2024 - Influx of New Products Including Orilissa, Relugolix and Bremelanotide to Diversify Landscape and Drive Growth" report has been added to ResearchAndMarkets.com's offering.
  • "Global Women's Health Drugs Market to 2024" covers all indications within women's health with a particular focus on five key indications: endometriosis, polycystic ovarian syndrome (PCOS), cervical intraepithelial neoplasia (CIN), menopausal disorders and infertility.
  • There are currently 277 pipeline products in active development for women's health, making it the 16th largest therapy area by pipeline size.
  • The global market is projected to grow at a compound annual growth rate (CAGR) of 5.16% till 2024.

Frontier Pharma: Women's Health - An Expanding Therapy Area, with Endometriosis Therapies Prominent among the First-in-Class Pipeline

Retrieved on: 
Wednesday, January 9, 2019
RTT, Women\'s health, Medicine, Health, Menstrual cycle, Gynaecological cancer, Endometriosis, Polycystic ovary syndrome, Intraepithelial neoplasia, Cervical intraepithelial neoplasia, Ovarian cancer, Menopause

NEW YORK, Jan. 9, 2019 /PRNewswire/ -- Frontier Pharma: Women's Health - An Expanding Therapy Area, with Endometriosis Therapies Prominent among the First-in-Class Pipeline

Key Points: 
  • NEW YORK, Jan. 9, 2019 /PRNewswire/ -- Frontier Pharma: Women's Health - An Expanding Therapy Area, with Endometriosis Therapies Prominent among the First-in-Class Pipeline
    The women's health therapy area covers medical disorders that affect females only, primarily disorders of the female reproductive system, including those associated with menstruation, conception, pregnancy, childbirth and menopause.
  • This reflects diagnostic barriers and high levels of non-treatment for women's health disorders, as well as high levels of genericization and relatively limited innovation within recent decades.
  • Consequently, there is strong rationale for continued R&D investment in women's health therapeutics due to high levels of unmet need across many indications.
  • This report assesses first-in-class innovation across the women's health therapy area, with a particular focus on three key indications: endometriosis, polycystic ovarian syndrome (PCOS) and cervical intraepithelial neoplasia (CIN).

Global Cytology Market 2018-2022 - Growing Popularity of Co-Testing / Consolidation and Automation of Laboratories / Advent of Cytology Imaging Systems

Retrieved on: 
Wednesday, December 19, 2018
Cancer, Infectious causes of cancer, Gynaecological cancer, RTT, Cytopathology, Medical tests, Pap test, Cervical cancer, Cervical intraepithelial neoplasia, Human papillomavirus infection, Intraepithelial neoplasia, Screening

The cytology market will register a CAGR of nearly 7% by 2022.

Key Points: 
  • The cytology market will register a CAGR of nearly 7% by 2022.
  • Pap test is used as a screening tools for cervical cancer has improved detection of cervical intraepithelial neoplasia.
  • Therefore, a substantial increase of HPV- associated cancers propels the demand for cytology testing and screenings methods.
  • According to the report, one of the major drivers for this market is the growing preference for liquid- based cytology tests.

Cervical Dysplasia Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 - 2024

Retrieved on: 
Thursday, May 24, 2018
Infectious causes of cancer, Gynaecological cancer, Medicine, Cervical intraepithelial neoplasia, Cervical cancer, Dysplasia, Anatomy, Cervical, Health

LONDON, May 24, 2018 /PRNewswire/ -- Global Cervical Dysplasia Market: Scope and Methodology

Key Points: 
  • LONDON, May 24, 2018 /PRNewswire/ -- Global Cervical Dysplasia Market: Scope and Methodology
    This report on the global cervical dysplasia market analyzes the current and future prospects of the market.
  • Growth rates for each segment within the global cervical dysplasia market have been determined after a thorough analysis of past trends, demographics, future trends, technological developments, and regulatory requirements.
  • This section of the report also includes market attractiveness analysis that provides a thorough analysis of the overall competitive scenario in the global cervical cancer market.
  • The global cervical dysplasia market is segmented as follows:
    Global Cervical Dysplasia Market Revenue, by Diagnosis